Published Date: 26 Apr 2023
Once a woman turns 40, experts advise that she at the very least think about starting a breast cancer screening program. According to a recent study, Black women need this advice above all others.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
2.
Drug-chemo combo increases cancer treatment efficacy
3.
Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma
4.
Indoor hydroponic gardening can improve mental health and quality of life for cancer patients
5.
Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
3.
Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes
4.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
Thromboprophylaxis In Medical Settings
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation